<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03047733</url>
  </required_header>
  <id_info>
    <org_study_id>AJIRB-MED-DE3-15-151</org_study_id>
    <nct_id>NCT03047733</nct_id>
  </id_info>
  <brief_title>Comparison of Cyclic On-off and Continuous Excimer Laser Treatment for Vitiligo</brief_title>
  <official_title>Comparison of Cyclic On-off and Continuous Excimer Laser Treatment for Vitiligo: A Randomized Controlled Non-inferiority Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ajou University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ajou University School of Medicine</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>No</is_unapproved_device>
    <is_ppsd>No</is_ppsd>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      OBJECTIVE: To investigate the efficacy of the cyclic on-off treatment compared to the
      conventional continuous excimer laser treatment.

      DESIGN: A randomized, controlled, split-body, non-inferiority study. SETTING: The trial was
      performed in two tertiary health care centers in Korea.

      PARTICIPANT: Twelve patients (16 pairs of lesions) with stable symmetric vitiligo less than 5
      years' disease duration were enrolled.

      INTERVENSION: The paired symmetric vitiliginous lesions were randomized to either the
      continuous or the cyclic on-off treatment. All lesions were treated twice weekly for 9-month:
      continuously, or cyclically with 2-month treatment and 1-month intermission (total 3 cycles).
      Topical tacrolimus was applied throughout the trial.

      OUTCOME MEASURES: The repigmentation was assessed using an image analysis program with
      clinical photographs. The primary outcome was mean difference of repigmentation rates and the
      non-inferiority margin was set at 10%. During intermission period, the clinical changes such
      as loss of repigmentation or worsening of the vitiligo lesions were assessed.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      [Study design and population] A randomized, controlled, split-body, non-inferiority trial was
      designed.

      After obtaining informed consent, 12 patients with stable symmetric vitiligo less than 5
      years' disease duration were enrolled.

      The patients taking systemic steroids or having enlarging lesions were excluded. The paired
      symmetric vitiliginous lesions were randomized to either the continuous or the cyclic excimer
      laser treatment.

      Total duration of study was 9 months.

      In cyclic excimer laser treatment, the cycle was arbitrarily determined that one cycle
      consists of a 2-month treatment period (on) and a consecutive 1-month intermission period
      (off) (total 3 cycles during the trial).

      [Treatment protocol]

      The lesions were treated twice a week. Initial irradiation dose was 50 mJ/cm2 on face and 100
      mJ/cm2 on trunk and extremities. If there had not been minimal asymptomatic erythema, energy
      level was escalated by 50 mJ/cm2. In cyclic treatment, the treatment resumed after
      intermission with the previously used irradiation dose.

      Topical tacrolimus 0.1% ointment was applied in both twice daily throughout whole length of
      the trial.

      [Assessment and primary outcome] Photographic documentation of lesions was conducted every
      month and the degree of repigmentation was assessed with a repigmentation rate (%) from the
      baseline by using an image analysis program (Digital Researcher for Vitiligo Area Evaluation,
      Dr. VAE, Korea).

      An intention-to-treat analysis was planned, and last observation carried forward method was
      applied to impute the missing value in the presence of dropouts.

      The primary outcome was mean difference of quantitative changes in repigmented area between
      continuous and cyclic on-off treatment. The non-inferiority margin was set at 10%. During
      intermission period in the cyclic treatment, the clinical changes such as loss of
      repigmentation or worsening of the vitiligo lesions were assessed.

      [Statistical analysis] All statistical analyses were conducted using R 3.2.4 (R Foundation
      for Statistical Computing, Austria) and a P value &lt;0.05 was considered statistically
      significant.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 21, 2015</start_date>
  <completion_date type="Actual">December 31, 2016</completion_date>
  <primary_completion_date type="Actual">December 31, 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>A randomized, controlled, split-body, non-inferiority trial.
Patients with stable symmetric vitiligo were enrolled. The paired symmetric vitiliginous lesions were randomized to either the continuous or the cyclic on-off excimer laser treatment.
Total duration of study was 9 months.
In cyclic on-off excimer laser treatment, the cycle was arbitrarily determined that one cycle consists of a 2-month treatment period (on) and a consecutive 1-month intermission period (off).</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean difference of quantitative changes in repigmented area between continuous and cyclic on-off treatment.</measure>
    <time_frame>Through study completion, an average of 9 months</time_frame>
    <description>The degree of repigmentation was assessed with a repigmentation rate (%) with clinical photographs by using an image analysis program (Digital Researcher for Vitiligo Area Evaluation, Dr. VAE, Korea).</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Dermatologic Disease</condition>
  <condition>Vitiligo</condition>
  <arm_group>
    <arm_group_label>continuously excimer laser treatment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>In this group, lesions treated twice weekly through out the whole trial length (9 months).
Application of topical tacrolimus 0.1% ointment through out the whole trial length (9 months).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>cyclic excimer laser treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In this group, one cycle consists of a 2-month treatment period (on) and a consecutive 1-month intermission period (off).
Total 3 cycles of cyclic treatment through out the whole trial length (9 months). During the treatment period, lesions treated twice weekly.
Application of topical tacrolimus 0.1% ointment through out the whole trial length (9 months).</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>The XTRAC Excimer Laser System</intervention_name>
    <description>Initial irradiation dose was 50 mJ/cm2 on face and 100 mJ/cm2 on trunk and extremities. If there had not been minimal asymptomatic erythema, energy level was escalated by 50 mJ/cm2.</description>
    <arm_group_label>continuously excimer laser treatment</arm_group_label>
    <arm_group_label>cyclic excimer laser treatment</arm_group_label>
    <other_name>XTRAC Velocity 400</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Topical tacrolimus 0.1% ointment</intervention_name>
    <description>Application of topical tacrolimus 0.1% ointment on the both lesions once daily.</description>
    <arm_group_label>continuously excimer laser treatment</arm_group_label>
    <arm_group_label>cyclic excimer laser treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with symmetric vitiligo

          -  Patients with less than 5 years' disease duration

        Exclusion Criteria:

          -  The patients taking systemic steroids

          -  The patients with currently enlarging lesions

          -  The patients who cannot follow the treatment schedule
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>10 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>HEE YOUNG KANG, M.D., Ph.D.</last_name>
    <role>Study Director</role>
    <affiliation>Ajou University School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ajou university hospital</name>
      <address>
        <city>Suwon-si</city>
        <state>Gyeonggi-do</state>
        <zip>16499</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <reference>
    <citation>Zhang XY, He YL, Dong J, Xu JZ, Wang J. Clinical efficacy of a 308 nm excimer laser in the treatment of vitiligo. Photodermatol Photoimmunol Photomed. 2010 Jun;26(3):138-42. doi: 10.1111/j.1600-0781.2010.00509.x.</citation>
    <PMID>20584252</PMID>
  </reference>
  <reference>
    <citation>Hofer A, Hassan AS, Legat FJ, Kerl H, Wolf P. Optimal weekly frequency of 308-nm excimer laser treatment in vitiligo patients. Br J Dermatol. 2005 May;152(5):981-5.</citation>
    <PMID>15888156</PMID>
  </reference>
  <reference>
    <citation>Park KK, Liao W, Murase JE. A review of monochromatic excimer light in vitiligo. Br J Dermatol. 2012 Sep;167(3):468-78. doi: 10.1111/j.1365-2133.2012.11008.x. Epub 2012 Aug 8. Review.</citation>
    <PMID>22524428</PMID>
  </reference>
  <results_reference>
    <citation>Aberdam E, Rom√©ro C, Ortonne JP. Repeated UVB irradiations do not have the same potential to promote stimulation of melanogenesis in cultured normal human melanocytes. J Cell Sci. 1993 Dec;106 ( Pt 4):1015-22.</citation>
    <PMID>7907336</PMID>
  </results_reference>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 5, 2017</study_first_submitted>
  <study_first_submitted_qc>February 7, 2017</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 9, 2017</study_first_posted>
  <last_update_submitted>February 7, 2017</last_update_submitted>
  <last_update_submitted_qc>February 7, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 9, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ajou University School of Medicine</investigator_affiliation>
    <investigator_full_name>Jae Min Sung</investigator_full_name>
    <investigator_title>Resident of the department of dermatology</investigator_title>
  </responsible_party>
  <keyword>Vitiligo</keyword>
  <keyword>308 nm excimer laser</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitiligo</mesh_term>
    <mesh_term>Skin Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tacrolimus</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

